EUVIMEDScopri EUVIMED
MetaanalyseSystematische ÜbersichtOpen access · CC BY 4.0

Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta‐analysis

James P Pham iD, Anthony Rodrigues, Simone M Goldinger iD, Hao-Wen Sim iD, Jia Liu iD

Experimental Dermatology · 2024-01 · 33 (1)

DOI: 10.1111/exd.14978 ↗

At a glance

Metaanalyse in Experimental Dermatology, published online on 2023-11-16. Written by James P Pham and 4 co-authors. Institution: Department of Medical Oncology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia. Major MEDLINE topics: Carcinoma, Squamous Cell, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Skin Neoplasms. Cited 17 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Patients with advanced cutaneous squamous cell carcinoma (cSCC) who are not eligible for or who fail to respond to anti‐PD1 immunotherapy have few treatment options. Epidermal growth factor receptor (EGFR) inhibitors have been investigated as a therapeutic option for advanced cSCC; however, data are limited to small single‐arm trials or retrospective studies. A systematic review and meta‐analysis was conducted to PRISMA guidelines (CRD42023394300). Studies reporting on outcomes of EGFR inhibition in advanced cSCC were identified. Objective response rate (ORR), progression‐free survival (PFS), overall survival (OS) and adverse event (AE) rate were pooled using a random effects model and the inverse variance method. Twelve studies (six prospective, six retrospective) were identified, representing 324 patients. Pooled ORR was 26% (95% confidence interval [CI] 18–36), median PFS was 4.8 months (95% CI 3.9–6.6) and median OS was 11.7 months (95% CI 9.2–14.1). Any grade AEs occurred in 93% of patients (95% CI 85–97) while grade 3 and higher AEs occurred in 30% (95% CI 14–54). These results were similar between anti‐EGFR monoclonal antibodies (MAbs) and tyrosine kinase inhibitors (TKIs). EGFR inhibitors can be considered in patients with advanced cSCC who are contraindicated for or progress on first‐line anti‐PD1 immunotherapy. Future studies should evaluate their activity and safety following anti‐PD1, identify predictive biomarkers for their efficacy and explore combination approaches.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Squamous CellCarcinoma, Non-Small-Cell LungLung NeoplasmsSkin NeoplasmsAntineoplastic AgentsHumansRetrospective StudiesProspective StudiesProtein Kinase InhibitorsErbB Receptors

Author keywords

EGFRSCCcutaneous squamous cell carcinomaepidermal growth factor receptor inhibitor

Substances

Protein Kinase InhibitorsAntineoplastic AgentsErbB Receptors

Authors and institutions

  • Department of Medical Oncology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.
  • School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Campus, Darlinghurst, New South Wales, Australia.
  • Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
  • NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia.
  • Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

ORCID profiles: James P Pham, Simone M Goldinger, Hao-Wen Sim, Jia Liu

Cite

APA

Pham, J. P., Rodrigues, A., Goldinger, S. M., Sim, H. W., & Liu, J. (2024). Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta‐analysis. Experimental Dermatology, 33(1). https://doi.org/10.1111/exd.14978

Vancouver

Pham JP, Rodrigues A, Goldinger SM, Sim HW, Liu J. Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta‐analysis. Experimental Dermatology. 2024;33(1). doi:10.1111/exd.14978

BibTeX
@article{Pham2024,
  author = {Pham, James P and Rodrigues, Anthony and Goldinger, Simone M and Sim, Hao-Wen and Liu, Jia},
  title = {Epidermal growth factor receptor inhibitors in advanced cutaneous squamous cell carcinoma: A systematic review and meta‐analysis},
  journal = {Experimental Dermatology},
  year = {2024},
  volume = {33},
  number = {1},
  doi = {10.1111/exd.14978}
}
Start for free →